The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot
NCT ID: NCT01480336
Last Updated: 2013-03-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
19 participants
INTERVENTIONAL
2011-02-28
2013-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ivabradine for Rate Control in Permanent Atrial Fibrillation
NCT03987204
Ranolazine Implantable Cardioverter-Defibrillator Trial
NCT01215253
Adenosine vs Diltiazem for Treatment of SVT in the ED
NCT06993038
Explorative Study of AZD1305 in Atrial Fibrillation Patients
NCT00643448
PERceptions of Diltiazem Versus ADEnosine for Treatment of Supraventricular Tachycardia in the Emergency Department
NCT07086560
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Amiodarone with Placebo
Amiodarone with Placebo
stabel dose of amiodarone as prescribed by cardiologist
Amiodarone with Ranolazine
Amiodarone Plus Ranolazine
Ranolazine 500mg by mouth twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amiodarone Plus Ranolazine
Ranolazine 500mg by mouth twice daily
Amiodarone with Placebo
stabel dose of amiodarone as prescribed by cardiologist
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with moderate or severe hepatic impairment (Child-Pugh Classes B or C) or requiring hemodialysis.
* Pregnancy or lactation.
* Treatment with potent CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, indinavir, and saquinavir
* Treatment with CYP3A inducers, including rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Hartford Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
William Baker, Pharm.D.
Role: PRINCIPAL_INVESTIGATOR
University of Connecticut
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hartford Hospital
Hartford, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KLUG003330HE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.